Drug Search Results
More Filters [+]

Dirocaftor

Alternative Names: dirocaftor, pti-808, pti808, pti 808
Latest Update: 2024-06-17
Latest Update Note: Clinical Trial Update

Product Description

Dirocaftor is a type of CFTR modulator called a potentiator.

Mechanisms of Action: CTFR Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Yumanity Therapeutics
Company Location: BOSTON MA 02135
Company CEO: Richard Peters
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dirocaftor

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HIT-CF-001

P2

Recruiting

Cystic Fibrosis

2025-06-30

HIT-CF-001

P3

Withdrawn

Cystic Fibrosis

2024-09-30

2017-003319-21

P2

Completed

Cystic Fibrosis

2019-12-23

PTI-808-01

P2

Completed

Cystic Fibrosis

2019-12-23

Recent News Events